Results 101 to 110 of about 5,328 (181)
Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST [PDF]
Taletrectinib; Non-small cell lung cancerTaletrectinib Cáncer de pulmón de células no pequeñasTaletrectinib; Càncer de pulmó de cèl·lules no petitesPurpose Taletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase ...
de Braud, Filippo Guglielmo Maria +6 more
core +1 more source
A Novel Oncogenic and Drug-Sensitive KIF5B-NTRK1 Fusion in Lung Adenocarcinoma
Current OncologyWe present a case of a lung adenocarcinoma patient harboring a novel kinesin family member 5B (KIF5B)-NTRK1 gene fusion that responds well to entrectinib.
Hui Li +6 more
doaj +1 more source
Spotlight on the treatment of ALK-rearranged non-small-cell lung cancer. [PDF]
, 2017 Jalal, Shadia I., Mamdani, Hirva
core +1 more source
Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
Drug Design, Development and Therapy, 2018 Holly L Pacenta, Margaret E Macy Department of Pediatrics, University of Colorado Anschutz Medical Campus and Children’s Hospital Colorado, Aurora, CO, USA Abstract: RTK plays important roles in many cellular signaling processes involved in ...
Pacenta HL, Macy ME
doaj
Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
Lung Cancer: Targets and Therapy, 2019 Francesco Facchinetti, Luc Friboulet INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, FranceCorrespondence: Francesco FacchinettiINSERM U981, Gustave Roussy Cancer Campus, 114 Rue Edouard, Villejuif 94800, FranceTel +
Facchinetti F, Friboulet L
doaj
Prospective Genomic Profiling Study in Sarcoma Patients
Indian Journal of Medical and Paediatric OncologyIntroduction Sarcoma is a heterogenous group of malignancy with diverse pathology and clinical behavior. Survival rates differ among histological subtypes, but overall prognosis remains poor due to the scarcity of effective systemic ...
Gwo Fuang Ho +5 more
doaj +1 more source
Withdrawal pain following patients discontinuing Trk inhibitors. [PDF]
OBJECTIVE: This article aims to expand on the existing literature regarding the incidence of withdrawal pain following discontinuation of Trk inhibitors and to explore strategies that mitigate this withdrawal pain.
Bergsland, Emily +3 more
core +1 more source
Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands [PDF]
Objectives: We evaluated the prognostic value of the neurotrophic tyrosine receptor kinase (NTRK) gene fusions by comparing the survival of patients with NTRK+ tumours with patients without NTRK+ tumours.
A Huygens, Simone +5 more
core +1 more source